Search

Displaying results 451 - 460 of 2507 in total
  1. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  2. Drug

    Bosutinib

    go.drugbank.com/drugs/DB06616
    ApprovedInvestigational

    -alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph … [A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  3. Drug

    PF-05230907

    go.drugbank.com/drugs/DB18417
    Investigational

    PF-05230907 is a recombinant activated Factor X variant.

  4. Drug

    TG100-115

    go.drugbank.com/drugs/DB05552
    Investigational

    An NSAID that inhibits PI-3K gamma and delta.

  5. Drug

    PF-06282999

    go.drugbank.com/drugs/DB11683
    Investigational

    Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects).

  6. Drug

    PH-797804

    go.drugbank.com/drugs/DB07941
    Investigational

    PH-797804 has been investigated for the treatment of Osteoarthritis.

  7. Drug

    PF-232798

    go.drugbank.com/drugs/DB14813
    Investigational

    PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).

    Synonyms: PF-00232798
  8. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    Belzutifan is an inhibitor of hypoxia-inducible factor 2α (HIF-2α) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers. The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medica...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  9. Drug

    Atazanavir

    go.drugbank.com/drugs/DB01072
    ApprovedInvestigational

    Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class.

    Categories: P-glycoprotein inducers, P-glycoprotein inhibitors
  10. Drug

    PD-98059

    go.drugbank.com/drugs/DB17042
    Experimental

    PD-98059 is an inhibitor of MAP-kinase kinase activation.[A253072]